医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Alzheon to Present at Upcoming Asian Healthcare and Scientific Conferences

2016年10月04日 PM09:30
このエントリーをはてなブックマークに追加


 

FRAMINGHAM, Mass.

Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that the company will be making presentations at several healthcare and scientific conferences in Asia during October, highlighting biotechnology innovation and drug development for Alzheimer’s disease.

Event:
BioCentury China Healthcare Summit

  • Title: Panel: International Perspective: Voices from Abroad
  • Presenter: Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
  • Date: Tuesday, October 18, at 5:05 p.m., local time
  • Location: Grand Hyatt Shanghai, Shanghai, China

Event:
10th International Congress of The Asian Society Against Dementia

  • Title: Symposium: Phase 3 Development of ALZ-801: Targeting Amyloid Pathology of Alzheimer’s Disease with an Oral Anti-Aggregation Agent
  • Presenters:
    Serge Gauthier, MD, FRCPC, Director of the Alzheimer’s Disease Research Unit at McGill University in Montreal, Canada, and member of Alzheon’s Scientific Advisory Board;
    Susan Abushakra, MD, Chief Medical Officer of Alzheon;
    Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
  • Date: Saturday, October 22, at 12:00 noon, local time
  • Location: Hangzhou Haiwaihai Crown Hotel, Hangzhou, China

Event:
China Renaissance Healthcare and Life Sciences Leadership Summit

  • Title: Panel: Overseas Biotechnology Sector
  • Presenter: Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
  • Date: Thursday, October 27, 2016 at 3:15 p.m.– 4:30 p.m., local time
  • Location: Dongjiao State Guest Hotel, Shanghai, China

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005167/en/

CONTACT

Media Contact:
The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 三井化学开发全球首款灵活的高强度柔性无纺布AIRYFA™
  • APR应用制药研究公司参加第9届ChinaBio®合作论坛:依托瑞士创新产品和科学技术深耕中国市场
  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定